Please ensure Javascript is enabled for purposes of website accessibility

Does Pfizer Deserve Its Latest 52-Week High?

By Alex Planes – Updated Apr 7, 2017 at 12:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A look back at Pfizer's big news and major moves.

Shares of Pfizer (NYSE: PFE) hit a 52-week high last week, which is in line with the performance of many of its peers over the past year. Let's look at what's driving these gains to better understand what the future holds for this company.

How it got here
The past year has been a pretty good one for shareholders of the larger drugmakers. Pfizer's performance has matched that of Merck (NYSE: MRK) over the 52-week period, and until Gilead Sciences (Nasdaq: GILD) took off following bullish analyst comments on its new HIV drug, it too had been on the same path. Gilead's fellow biotech heavyweight Amgen (Nasdaq: AMGN) is also dancing in the range of 50% year-over-year gains:

PFE Total Return Price Chart

PFE Total Return Price data by YCharts

Johnson & Johnson (NYSE: JNJ) has lagged over the past year as investors grapple with whether the company's historically stable dividend is worth the risk of potentially poor forward growth. That's something Pfizer shareholders should be keenly aware of, since it faces a steep patent cliff in the next few years. In fact, the stability of these drugmakers' dividends may be driving the entire group to higher prices, as every company but Merck has seen its stock's P/E grow by at least 25% over the last year:

PFE P/E Ratio Chart

PFE P/E Ratio data by YCharts

Pfizer's current P/E is fairly consistent with its five-year average, but is higher than the sub-15 P/Es its stock regularly earned before 2011. To make sure that this isn't anything to worry about, we'd better dig into some key stats for both Pfizer and its peers.

What you need to know
Pfizer's P/E is one of the cheapest in this group, but only by a narrow margin:

Company

P/E Ratio

Net Margin (TTM)

Projected Growth Rate (2013)

Dividend Yield

Pfizer 18.4 15.8% 5.0% 3.6%
Merck 20.5 13.9% (3.1%) 3.8%
Gilead Sciences 20.5 28.4% 15.9% NM
Amgen 18.0 23.4% 9.3% 1.7%
Johnson & Johnson 21.9 13.5% 6.4% 3.6%

Source: Yahoo! Finance.

The patent cliff is an obvious threat, but Pfizer's growth may be further crimped as it sells off its animal health subsidiary as Zoetis next year. There are some drugs coming through the pipeline that could blunt the impact of these drop-offs, most notably those treating chronic myeloid leukemia and rheumatoid arthritis, and a potential blockbuster blood thinner. My fellow Fool Keith Speights doesn't see anything stepping into Lipitor's big shoes, which might drop Pfizer's actual growth rate into the red with Merck's.

What's next?
Falling off a cliff is never a joke, but Pfizer shareholders seem to think they've got parachutes strapped to their backs as they step to the edge. The company's 62% dividend payout ratio is a bit high for comfort, especially with the risk of reduced earnings ahead. Pfizer's managed to keep profit stable even as revenue declines, but there's only so much efficiency to be squeezed out of a system that's soon to have potent generic competition.

The Motley Fool's CAPS community has given Pfizer a four-star rating, with 90% of our CAPS players expecting the company to beat the indexes going forward. Patent cliff? Pshaw. The CAPS community has their parachutes on.

Interested in tracking this stock in the months and years ahead? Add Pfizer to your Watchlist now, for all the news we Fools can find, delivered to your inbox as it happens. Pfizer's dividend might be in danger, but you don't have to go over the patent cliff with its payouts. To discover three great dividend stocks that don't have any cliffs to cross, check out the Fool's latest free report. It's got everything you need for an informed buy, and you can claim this important information at no cost by clicking here.

Fool contributor Alex Planes holds no financial position in any company mentioned here. Add him on Google+ or follow him on Twitter @TMFBiggles for more news and insights.

The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Gilead Sciences and Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.91 (-0.38%) $0.17
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.34 (-0.51%) $0.44
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.59 (-0.68%) $-1.13
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.64 (-0.35%) $0.22
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$227.22 (0.11%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.